Gaviscon Liquid Peppermint Flavour, Oral Suspension Sodium alginate 500 mg Sodium bicarbonate 267 mg Calcium carbonate 160 mg

Země: Irsko

Jazyk: angličtina

Zdroj: HPRA (Health Products Regulatory Authority)

Aktivní složka:

Sodium alginate; Calcium carbonate; Sodium bicarbonate

Dostupné s:

Reckitt Benckiser Ireland Ltd

ATC kód:

A02AX

INN (Mezinárodní Name):

Sodium alginate; Calcium carbonate; Sodium bicarbonate

Dávkování:

500 mg+267 mg+160 milligram(s)

Léková forma:

Oral suspension

Druh předpisu:

Product not subject to medical prescription

Terapeutické oblasti:

Antacids, other combinations

Stav Autorizace:

Marketed

Datum autorizace:

1996-01-03

Informace pro uživatele

LEAFLET TEXT
PACKAGE LEAFLET: INFORMATION FOR THE USER
Gaviscon Liquid Peppermint Flavour Oral Suspension
Sodium alginate 500mg/10ml, Sodium bicarbonate 267mg/10ml, Calcium
carbonate 160mg/10ml
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
This medicine is available without prescription. However you still
need to take this medicine carefully to
get the best results from it.
Always use this medicine exactly as described in this leaflet or as
your doctor, pharmacist or nurse has
told you.

Keep this leaflet. You may need to read it again.

Ask your pharmacist if you need more information or advice.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.

You must talk to a doctor if you do not feel better or if you feel
worse after 7 days
WHAT IS IN THIS LEAFLET
1.
What is Gaviscon Liquid and what is it used for?
2.
what you need to know before taking Gaviscon Liquid
3.
How to take Gaviscon Liquid
4.
Possible side-effects
5.
How to store Gaviscon Liquid
6.
Contents of the pack and other information.
1.
WHAT IS THIS MEDICINE AND WHAT IS IT USED FOR?
Gaviscon Liquid belongs to a group of medicines called “reflux
suppressants”. This product forms a
protective layer that floats on top of the stomach contents. This
layer prevents reflux and keeps the
stomach contents away from the lining of the food pipe to relieve the
symptoms of heartburn and acid
indigestion.
This medicine is used for the treatment of symptoms of
gastro-oesophageal reflux such as acid
regurgitation, heartburn and indigestion (related to reflux), for
example, following meals, or during
pregnancy, or in patients with symptoms related to reflux
oesophagitis.
2.
BEFORE TAKING THIS MEDICINE
DO NOT TAKE GAVISCON LIQUID:

If you know you are allergic (hypersensitive) to any of the
ingredients in this product (see “further
information” for a full list of ingredie

Charakteristika produktu

Health Products Regulatory Authority
25 January 2021
CRN0099WQ
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon Liquid Peppermint Flavour, Oral Suspension Sodium alginate
500 mg Sodium bicarbonate 267 mg Calcium carbonate
160 mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10 ml contains 500 mg sodium alginate, 267 mg sodium bicarbonate
and 160 mg calcium carbonate.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Oral Suspension
Viscous, opaque, off-white to cream, peppermint flavoured supension.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
500 AND 600 ML
For the management of gastric reflux, reflux oesophagitis, hiatus
hernia, heartburn (including heartburn of pregnancy) and
similar gastric distress.
100, 150 AND 300 ML
For the relief of stomach upset due to hyperacidity and heartburn
(including heartburn of pregnancy).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
500 AND 600 ML
Adults and children over 12 years: 10-20 ml (two to four 5 ml
spoonfuls) after meals and before retiring.
100, 150 AND 300 ML
Adults and children over 12 years: 10-20 ml (two to four 5 ml
spoonfuls) after meals and before retiring.
Children under 12 years: Should be given only on medical advice.
Not for use in children of 6 years or under.
DURATION OF TREATMENT
If symptoms do not improve after seven days, the clinical situation
should be reviewed.
SPECIAL PATIENT GROUPS
Elderly: No dosage modification is required in this age group.
Hepatic Impairment: No modifications necessary.
Renal Insuffiency: Caution if highly restricted salt diet is
necessary.
METHOD OF ADMINISTRATION
For oral administration
Health Products Regulatory Authority
25 January 2021
CRN0099WQ
Page 2 of 4
4.3 CONTRAINDICATIONS
Hypersensitivity to Sodium alginate, Sodium bicarbonate, and Calcium
carbonate or any of the excipients listed in section 6.1,
including methyl parahydroxybenzoate (E218) and propyl
parahydroxybenzoate (E216) (see section 4.4.).
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If symptoms do not impro